Managing Dyslipidemia in Turkey: Suggeested guidelines for a population characterized by low levels of high density lipoprotein cholesterol;Türkiye'de Dislipideminin Takibi

Anadolu Kardiyoloji Dergisi

Volumn 2, Issue 4, 2002, Pages 315-322

  Bersot, Thomas P ^a,b   Palaoǧlu, K Erhan ^b   Mahley, Robert W ^a,b  

^a AMERICAN HOSPITAL   (Turkey)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coronary heart disase; High density lipoproteins; Plasma cholesterol; Statins; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; DRUG INDICATION; DYSLIPIDEMIA; FEMALE; HEREDITY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; MEDICAL SOCIETY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; TURKEY (REPUBLIC); UNITED STATES; WESTERN EUROPE;

CHOLESTEROL; CHOLESTEROL, HDL; CORONARY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; PRACTICE GUIDELINES; RISK FACTORS; SMOKING; TRIGLYCERIDES; TURKEY;

EID: 19244369022     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: Guidance from Framingham. A statement for healthcare professionals from the AHA Task Force on Risk Reduction. Circulation 1998; 97: 1876-87.
2. Onat A, Senocak MS, Surdum-Avci G, Örnek E. Prevalence of coronary heart disease in Turkish adults. Int J Cardiol 1993; 93: 23-31.
3. Onat A, Dursunoǧlu D, Sansoy V. Relatively high coronary death and event rates in Turkish women. Relation to three major risk factors in five-year follow-up of cohort. Int J Cardiol 1997; 61: 69-77.
4. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156: 1-10.
5. Mahley RW, Palaoǧlu KE, Atak Z, et al. Turkish Heart Study: Lipids, lipoproteins, and apolipoproteins. J Lipid Res 1995; 36: 839-59.
6. National Cholesterol Education Program Expert Panel: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-97.
7. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Summary of recommendations. Eur Heart J 1998; 19: 1434-503.
8. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. J Am Med Assoc 1986; 256: 2835-8.
9. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
10. Onat A, Yildirim B, Uslu N, et al. Plasma lipoproteins and apolipoproteins in Turkish adults: Overall levels, associations with other risk parameters and HDL's role as a marker of coronary risk in women (in Turkish). Arch Turk Soc Cardiol 1999; 27: 72-9.
11. National Center for Health Statistic. Centers for Disease Control: Table 3. Serum high density lipoprotein (HDL) cholesterol of males 4 years of age and older by age: Mean and selected percentiles, United States, 1988-94. Available at: http://www.cdc.gov/nchs/about/major/nhanes.pdf. Accessed August 15,2002
12. National Center for Health Statistics. Centers for Disease Control: Table 4. Serum high density lipoprotein (HDL) cholesterol of females 4 years of age and older by age: Mean and selected percentiles, United States, 1988-94. Available at: http://www.cdc.gov/nchs/about/major/nhanes/hdlfem.pdf. Accessed August 15, 2002
13. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
14. Knuiman JT, West CE, Katan MB, Hautvast JGAJ. Total cholesterol and high density lipoprotein cholesterol levels in populations differing in fat and carbohydrate intake. Arteriosclerosis 1987; 7: 612-9.
15. Criqui MH, Wallace RB, Heiss G, Mishkel M, Schonfeld G, Jones GTL. Cigarette smoking and plasma high-density lipoprotein cholesterol. The Lipid Research Clinics Program Prevalence Study. Circulation 1980; 62 (Suppl. 4): IV-7-6.
16. Enger SC, Herbjørnsen K, Erikssen J, Fretland A. High density lipoproteins (HDL) and physical activity: The influence of physical exercise, age and smoking on HDL-cholesterol and the HDL-/total cholesterol ratio. Scand J Clin Lab Invest 1977; 37: 251-5.
17. Ernst N, Fisher M, Smith W, et al. The association of plasma high-density lipoprotein cholesterol with dietary intake and alcohol consumption. The Lipid Research Clinics Program Prevalence Study. Circulation 1980; 62: IV-41-IV-52.
18. Contaldo F, Strazzullo P, Postiglione A, et al. Plasma high density lipoprotein in severe obesity after stable weight loss. Atherosclerosis 1980; 37: 163-7.
19. Wallace RB, Hunninghake DB, Reiland S, et al. Alterations of plasma high-density lipoprotein cholesterol levels associated with consumption of selected medications. The Lipid Research Clinics Program Prevalence Study. Circulation 1980; 62: IV-77-IV-82.
20. Glueck CJ, Taylor HL, Jacobs D, Morrison JA, Beaglehole R, Williams OD. Plasma high-density lipoprotein cholesterol: Association with measurements of body mass. The Lipid Research Clinics Program Prevalence Study. Circulation 1980; 62: IV-62-9.
21. Hartung GH, Foreyt JP, Mitchell RE, Vlasek I, Gotto AM, Jr. Relation of diet to high-density- lipoprotein cholesterol in middle-aged marathon runners, joggers and inactive men. N Engl J Med 1980; 302: 357-61.
22. Bersot TP, Vega GL, Grundy SM, et al. Elevated hepatic lipase activity and low levels of high density lipoprotein in a normotriglyceridemic, nonobese Turkish population. J Lipid Res 1999; 40: 432-8.
23. Mahley RW, Pépin J, Palaoǧlu KE, Malloy MJ, Kane JP, Bersot TP. Low levels of high density lipoproteins in Turks, a population with elevated hepatic lipase: High density lipoprotein characterization and gender-specific effects of apolipoprotein E genotype. J Lipid Res 2000; 41: 1290-301.
24. Lüttmann S, von Eckardstein A, Wei W, et al. Electrophoretic screening for genetic variation in apolipoprotein C-III: Identification of a novel apoC-III variant, apoC-III (Asp45n), in a Turkish patient. J Lipid Res 1994; 35: 1431-40.
25. Duriez P, Fruchart JC. High-density lipoprotein subclasses and apolipoprotein A-I. Clin Chim Acta 1999; 286: 97-114.
26. Assmann G, von Eckardstein A, Brewer HB, Jr. Familial analphalipoproteinemia: Tangier disease. In: Scriver CR, Beaudet AL, Sly WS, et al. (editors). The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001. p. 2937-2960.
27. Breslow J. Insights into lipoprotein metabolism from studies in transgenic mice. Annu Rev Physiol 1994; 56: 797-810.
28. Sviridov D, Nestel P. Dynamics of reverse cholesterol transport: Protection against atherosclerosis. Atherosclerosis 2002; 161: 245-54.
29. von Eckardstein A, Huang Y, Assmann G: Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol 1994; 5: 404-16.
30. Puchois P, Kandoussi A, Fievet P, et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987; 68: 35-40.
31. Vega Gl, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol 1996; 7: 209-16.
32. Mahley RW, Arslan P, Pekcan G, et al. Plasma lipids in Turkish children: Impact of puberty, socioeconomic status, and nutrition on plasma cholesterol and HDL. J Lipid Res 2001; 42: 1996-2006.
33. Freedman DS, Srinivasan SR, Cresanta Jl, Webber LS, Berenson GS. Serum lipids and lipoproteins. Pediatrics 1987; 80 (Suppl.): 789-96.
34. Webber LS, Srinivasan SR, Wattigney WA, Berenson GS. Tracking of serum lipids and lipoproteins from childhood to adulthood. The Bogalusa Heart Study. Am J Epidemiol 1991; 133: 884-99.
35. Brotons C, Ribera A, Perich RM, et al. Worldwide distribution of blood lipids and lipoproteins in childhood and adolescence: A review study. Atherosclerosis 1998; 139 1-9.
36. Berenson GS, Srivivasan SR, Frerichs RR, Webber LS. Serum high density lipoprotein and its relationship to cardiovascular disease risk factor variables in children-The Bogalusa Heart Study. Lipids 1979; 14: 91-8.
37. Aguilera F, Lupianẽz L, Magaña D, Planells E, Mataix FJ, Llopis J. Lipid status in a population of Spanish schoolchildren. Eur J Epidemiol 1996; 12: 135-40.
38. McKeigue PM, Shah B, Marmot MG: Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 1991; 337: 382-6.
39. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995; 75: 473-86.
40. Haffner SM, D'Agostino R, Jr., Saad MF, et al. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites: The Insulin Resistance Atherosclerosis Study. Diabetes 1996; 45: 742-8.
41. Katzmarzyk PT, Pérusse L, Malina RM, Bergeron J, Després J-P, Bouchard C. Stability of indicators of the metabolic syndrome from childhood and adolescence to young adulthood: The Québec Family Study. J Clin Epidemiol 2001; 54: 190-5.
42. Gower BA. Syndrome X in children: Influence of ethnicity and visceral fat. Am J Hum Biol 1999; 11: 249-57.
43. Reddy KS. Primordial prevention of coronary heart disease in India: Challenges and opportunities. Prev Med 1999; 29: S119-23.
44. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999; 83: 25F-9F.
45. Kannel WB. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol 1988; 62: 1109-112.
46. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. J Am Med Assoc 1998; 279: 1615-22.
47. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8.
48. MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience. Eur Heart J 1999; 20: 725-41.
49. Gotto Am, Jr., Whitney E, Stein EA, et al. Relation between baseline and on treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study. (AFCAPS/ TexCAPS). Circulation 2000; 101: 477-84.
50. Downs JR, Beere PA, Whitney E, et al. Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 1997; 80: 287-93.
51. Mahley RW, Pépin GM, Bersot TP, Palaoǧlu KE, Özer K. Turkish Heart Study update: Plasma lipids and treatment guidelines for patients with low levels of high density lipoproteins (in Turkish). Arch Turk Soc Cardiol 2002; 30: 93-103.
52. Schaefer EJ, Lamon-Fava S, Ordovas JM, et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-1 levels in the Framingham Offspring Study. J Lipid Res 1994; 35: 871-82.